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Summary Dyspnoea measurements in chronic obstructive pulmonary disease
(COPD) can be broadly divided into two categories: those that assess breathlessness
during exercise, and those that assess breathlessness during daily activities. We
investigated the relationships between dyspnoea at the end of exercise and during
daily activities with clinical measurements and mortality in COPD patients.
We examined 143 male outpatients with moderate to very severe COPD. The peak
Borg score at the end of progressive cycle ergometry was used for the assessment of
peak dyspnoea rating during exercise, and the Baseline Dyspnea Index (BDI) scoreee front matter & 2005
med.2005.10.006
s: BDI, Baseline Dyspne
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ess: ogat@df7.so-net.nwas used for dyspnoea with activities of daily living. Relationships between these
dyspnoea ratings with other clinical measurements of pulmonary function, exercise
indices, health status and psychological status were then investigated. In addition,
their relationship with the 5-year mortality of COPD patients was also analyzed to
examine their predictive ability.
Although the BDI score was significantly correlated with airflow limitation,
diffusing capacity, exercise indices, health status and psychological status, the Borg
score at the end of exercise had non-existent or only weak correlations with them.
The BDI score was strongly significantly correlated with mortality, whereas the Borg
score was not.Elsevier Ltd. All rights reserved.
a Index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s;
Scale; HR, heart rate; RV, residual volume; SaO2, arterial oxygen saturation; SGRQ, St. George’s
lung capacity; TLCO, carbon monoxide transfer factor; _VE, minute ventilation; _VO2 , oxygen
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T. Oga et al.966Dyspnoea during daily activities was more significantly correlated with objective
and subjective measurements of COPD than dyspnoea at the end of exercise. In
addition, the former was more predictive of mortality. Dyspnoea with activities of
daily living is considered to be a better measurement for evaluating the disease
severity of COPD than peak dyspnoea during exercise.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Exertional dyspnoea is one of the most common
complaints of patients with chronic obstructive
pulmonary disease (COPD), and often leads these
patients to seek medical attention, although the
mechanism responsible for dyspnoea is complex
and multifactorial.1 However, dyspnoea can be
relatively easily measured in clinical settings, and
is evaluated under various circumstances in pa-
tients with COPD.
The outcome measurements of dyspnoea can be
broadly divided into those that assess breathless-
ness during exercise, and those that assess overall
breathlessness during daily activities.2 The rela-
tionships between dyspnoea during daily activities
and other objective or subjective measurements3–5
or mortality6,7 have been reported, and its mea-
surement is recommended as an indicator of
disease severity in COPD management guide-
lines.8,9
In comparison, it is still uncertain what research-
ers actually evaluate by measuring peak dyspnoea
during exercise, and whether it is related to disease
severity in COPD. Furthermore, peak dyspnoea has
been reported to evaluate different aspects from
dyspnoea with activities of daily living.4 Therefore,
in the present study, we investigated what peak
dyspnoea during exercise actually represented in
patients with COPD, and whether it was related to
mortality in order to investigate its relationship
with disease severity, and compared it with
dyspnoea during daily activities.Methods
Subjects
We previously recruited male outpatients with
COPD from the Kyoto University Hospital, and
analyzed the relationships between baseline clin-
ical parameters and mortality, focusing on exercise
capacity and health status.10 In the present study,
we retrospectively reviewed these data and re-
analyzed the relationships between the dyspnoeameasurements during exercise and during daily
activities, as well as other clinical parameters and
mortality, in 143 patients with moderate to very
severe COPD. The definition of COPD was based on
published guidelines,8 and the subjects met the
following criteria: (1) a smoking history of more
than 20 pack-years; (2) maximal forced expiratory
volume in 1 s (FEV1)/forced vital capacity (FVC)
ratio of less than 0.7 and a postbronchodilator FEV1
of less than 80% of the predicted value; (3) no
uncontrolled comorbidities likely to affect mortal-
ity such as malignant disorders, cardiovascular
diseases or cerebrovascular diseases; (4) regular
attendance of over 6 months; and (5) no exacer-
bations in the preceding 6 weeks. Pulmonary
function testing, progressive cycle ergometry, and
the assessments of dyspnoea, health status, psy-
chological status and body mass index (BMI) were
performed on the same day. The present study was
performed as part of our standard outpatient
treatment and care.Measurements
Pulmonary function
Pulmonary function tests were performed at least
12 h after the withdrawal of inhaled bronchodila-
tors. According to the recommended method,11 the
subjects underwent spirometry before and at 15
and 60min after inhaling salbutamol (400 mg) and
ipratropium bromide (80 mg), using a metered-dose
inhaler with a spacer device (InspirEaseTM, Scher-
ing-Plough K.K., Osaka, Japan). The residual
volume (RV) was measured by the closed-circuit
helium method, and the carbon monoxide transfer
factor (TLCO) was measured by the single-breath
technique (CHESTAC-65V, Chest, Tokyo, Japan).
Predicted values were based on data from the
Japan Society of Chest Diseases.12Exercise tests
Symptom-limited progressive cycle ergometry was
performed at 60min after the inhalation of
bronchodilators on a calibrated, electrically braked
cycle ergometer, as described in detail else-
where.13 The patients wore a face mask and began
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workload was increased progressively by incre-
ments of 1W every 3 s to the limit of tolerance.
The exercise data were recorded using an auto-
mated exercise testing system. Minute ventilation
( _VE) and oxygen tension in the expired air were
determined every eight breaths, and the mean _VE,
oxygen uptake ( _VO2) and carbon dioxide production
were then calculated. The peak values were
defined as the highest levels reached during
exercise. Arterial oxygen saturation (SaO2) was
measured through pulse oximetry, and the heart
rate (HR) was recorded electrocardiographically. At
the end of the exercise, the symptoms of breath-
lessness were scored with the Borg scale (0–10),14
with 0 indicating the absence of dyspnoea and 10
representing ‘‘the most severe level of dyspnoea
you could imagine or have ever undergone’’.Clinical dyspnoea
Dyspnoea during daily activities was evaluated by
the Japanese version of the Baseline Dyspnea Index
(BDI).4,15 The BDI recognizes five grades from 0
(severe) to 4 (not impaired) for each of the
following three categories: functional impairment,
magnitude of task, and magnitude of effort.Table 1 Baseline characteristics in 143 male
patients with COPD.
Characteristic Mean7SDHealth status
Health status was measured by the St. George’s
Respiratory Questionnaire (SGRQ)16 whose Japa-
nese version has been previously validated.17 The
SGRQ consists of 50 items divided into three
components of symptoms, activity and impacts,
and the total score was also calculated, with scores
ranging from 0 to 100. Lower scores indicate less
impairment on the SGRQ.Age, years 68.876.7
Body mass index (kg/m2) 21.072.9
Postbronchodilator FEV1, %
predicted
45.7715.9
RV/TLC (%) 47.1710.3
TLCO, % predicted 64.7720.3
Exercise data
Borg score at the end of
exercise (0–10)
6.571.5
Peak _VO2 (mL/min)
8177256
_ 40711Psychological status
Psychological status related to anxiety and depres-
sion was evaluated by the Japanese version of the
Hospital Anxiety and Depression Scale (HADS).17,18
It consists of 14 items, seven for anxiety and seven
for depression. Each item is scored from 0 to 3,
where 3 represents a state corresponding to the
worst anxiety or depression. The sum of these items
produces 2 subscales ranging from 0 to 21.Peak VE (L/min)
Lowest SaO2 (%) 9175
Peak HR, beats/min 125718
BDI (0–12) 7.972.6
SGRQ total (0–100) 36.7716.3
HADS anxiety (0–21) 3.973.4
HADS depression (0–21) 4.773.7
The numbers in parentheses indicate the theoretical
score range.Follow-up data
Among the 143 COPD patients, five were unavail-
able for follow-up and 31 died during the 5-year
period. With respect of the causes of deaths, 20
died of COPD or COPD-related disease, four due to
malignant disorders, and one each due to myocar-dial infarction and hepatic failure, respectively.
Five deaths were due to unknown causes.
Statistical analysis
The results are presented as mean7SD, unless
otherwise stated. The relationships between the
dyspnoea scores and other clinical measurements
were analyzed by Spearman’s rank correlation
tests. When significant relationships were ob-
served, stepwise multiple regression analyses were
performed to identify those variables that could
best predict the dyspnoea score, using the variables
that were significantly correlated to it as explana-
tory variables.17
The survival status of all subjects after 5 years
was assessed. The duration from entry to the last
attendance or death was then recorded. Univariate
Cox proportional hazards analyses were performed
to investigate the relationship between the clinical
indices and mortality. The results of the regression
analysis were presented in terms of the estimated
relative risks (RR) with the corresponding 95%
confidence intervals (CI). P values of less than
0.05 were considered to be statistically significant.Results
The baseline characteristics of the patients with
COPD are presented in Table 1. Their average age
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T. Oga et al.968was 68.876.7 years, and the postbronchodilator
FEV1 was 1.2170.43 L and 45.7715.9% predicted.
The peak dyspnoea during exercise evaluated by
the Borg score at the end of progressive cycle
ergometry was 6.571.5, and the dyspnoea with
activities of daily living evaluated by the BDI score
was 7.972.6. The frequency distributions of the
Borg score at the end of exercise and the BDI score
in COPD patients are shown in Fig. 1. These
histograms showed virtually normal distributions.
Table 2 shows the Spearman’s rank correlation
coefficients (Rs) between the dyspnoea scores and
various clinical variables. The Borg score at the end
of exercise was significantly correlated with post-
bronchodilator FEV1 (Rs ¼ 0:27, P ¼ 0:0017), the
health status score evaluated by the SGRQ
(Rs ¼ 0:31, P ¼ 0:0002), and the depression score
from the HADS (Rs ¼ 0:19, P ¼ 0:026). In contrast,
the BDI score was significantly correlated with
pulmonary function from postbronchodilator FEV1
and TLCO, and the exercise indices of peak _VO2,
peak _VE, lowest SaO2 and peak HR (Rs ¼ 0:2220:46,
Po0:05). The BDI was also moderately correlated
with the health status by the SGRQ (Rs ¼ 0:71,
Po0:0001) and with anxiety and depression from
the HADS (Rs ¼ 0:31, P ¼ 0:0002; and Rs ¼ 0:44,
Po0:0001, respectively). These significant rela-
tionships of the BDI with other objective and
subjective measurements were stronger than those
of the peak Borg score, judging from the Spear-
man’s rank correlation coefficients. The relation-Table 2 Spearman’s rank correlation coefficients
between the dyspnoea scores and other clinical
variables.
Borg score
at the end
of exercise
BDI score
Age — —
Body mass index — —
Postbronchodilator FEV1 0.27 0.30
RV/TLC — —
TLCO — 0.34
Exercise data
Peak _VO2
— 0.46
Peak _VE — 0.30
Lowest SaO2 — 0.23
Peak HR — 0.22
SGRQ total 0.31 0.71
HADS anxiety — 0.31
HADS depression 0.19 0.44
Missing data (—) indicate that there were not statistically
significant relationships.
Figure 1 Frequency distributions of the Borg score at the
end of exercise (A) and the BDI score (B) in patients with
COPD. On the Borg score, lower scores indicate less
dyspnoea, and on the BDI score, lower scores indicate
more severe dyspnoea.ship between the Borg score and the BDI score was
significant but weak (Rs ¼ 0:33, Po0:0001).
Table 3 shows the stepwise multiple regression
analyses performed to identify those variables that
could best predict the dyspnoea scores. Regarding
the Borg score at the end of exercise, the SGRQ
total score and FEV1 accounted for 8% and 5% of the
variance, respectively. Regarding the BDI, the SGRQ
total score significantly accounted for 50% of the
variance, and the lowest SaO2 also accounted for
4% of the variance.
Table 4 shows the results from the univariate Cox
proportional hazards model in analyzing the rela-
tionship between dyspnoea and the other major
clinical measures with mortality in COPD. The Borg
score at the end of exercise was not significantly
correlated with all causes and COPD-related mor-
tality in COPD (RR ¼ 1:084, P ¼ 0:51; and RR ¼
1:030, P ¼ 0:85, respectively). In comparison, the
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causes and COPD-related mortality (RR ¼ 0:824,
P ¼ 0:0049; and RR ¼ 0:792, P ¼ 0:0061, respec-
tively). BMI, FEV1, RV/total lung capacity (TLC),
TLCO, peak _VO2 and the SGRQ total score had
significant correlations with mortality, although
the psychological status evaluated by the HADS
did not.Discussion
We found out that the Borg score at the end of
progressive cycle ergometry was less significantlyTable 4 Univariate Cox proportional hazards analyses on
and mortality.
All deaths
Relative risk (95% CI) P
Borg score 1.084 (0.853–1.378)
BDI 0.824 (0.720–0.943)
BMI (kg/m2) 0.795 (0.693–0.911)
FEV1, % predicted 0.944 (0.918–0.970) o
RV/TLC (%) 1.069 (1.033–1.105)
TLCO, % predicted 0.948 (0.926–0.972) o
Peak _VO2 (mL/min)
0.994 (0.992–0.996) o
SGRQ total 1.032 (1.011–1.054)
HADS anxiety 1.033 (0.933–1.144)
HADS depression 1.078 (0.984–1.182)
Table 3 Relative contribution of each variable to
the dyspnoea scores on the stepwise multiple
regression analyses.
Borg score at
the end of
exercise
BDI score
Postbronchodilator
FEV1
0.05 —
TLCO —
Peak _VO2
—
Peak _VE —
Lowest SaO2 0.04
Peak HR —
SGRQ total 0.08 0.50
HADS anxiety —
HADS depression — —
Cumulative R2 0.13 0.54
Missing data (—) indicate that the independent variables
were not statistically significant.
All values represent coefficients of determination (R2).correlated with pulmonary function, exercise in-
dices, health status and psychological status than
the BDI score. In addition, we demonstrated that
although health status and airflow limitation
accounted for the Borg score at the end of exercise,
their relative contributions were very small.
Furthermore, this peak score was not significantly
correlated with all causes and COPD-related mor-
tality, which contrasted with the strong and
significant relationship of the BDI score with
mortality.
As compared to dyspnoea during daily activities,
there is still more study required for investigating
the properties of peak dyspnoea during exercise.
Physicians measure dyspnoea during exercise in
COPD in order to identify those patients with more
severe exertional dyspnoea (discriminatory pur-
poses), and to investigate the benefits of some
interventions (evaluative purposes).19 The near
normal distribution in Fig. 1 shows that the Borg
score at the end of exercise has discriminatory
power like the BDI. However, regarding its evalua-
tive property, peak dyspnoea during exercise some-
times shows no significant changes after an
intervention which is apparently beneficial by other
measurements.13,20–24 By calculating the dyspnoea
rating at isotime or expressed over the slopes of
time, _VO2 or
_VE, exertional dyspnoea became an
improved outcome.13,20–22
The ability to predict mortality (predictive
property) is important in COPD,10,25 in addition to
discriminatory and evaluative properties, consider-
ing that COPD is ranked high as a cause of death in
the world.26 In the present study, peak dyspnoea on
progressive cycle ergometry was not well corre-
lated with mortality in COPD, unlike the BDI. It
should be noted that the relationship of dyspnoea
with mortality was completely different accordingthe relationship between major clinical measurements
COPD deaths
value Relative risk (95% CI) P value
0.51 1.030 (0.763–1.392) 0.85
0.0049 0.792 (0.670–0.935) 0.0061
0.0010 0.786 (0.659–0.939) 0.0078
0.0001 0.909 (0.871–0.948) o0.0001
0.0001 1.092 (1.047–1.139) o0.0001
0.0001 0.945 (0.916–0.975) 0.0004
0.0001 0.994 (0.991–0.996) o0.0001
0.0024 1.039 (1.013–1.066) 0.0028
0.53 0.992 (0.867–1.134) 0.90
0.11 1.040 (0.923–1.171) 0.52
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versus during daily activities. The predictive
property of peak dyspnoea during exercise has not
been well investigated thus far. Barreiro et al.27
recently reported that blunted dyspnoea at the end
of exercise was a good predictor of near fatal
asthma, and asthma is a disease characterized by
airflow limitation and breathlessness, like COPD.
However, in COPD, it is difficult to postulate that
peak dyspnoea during exercise reflects disease
severity from the viewpoint of mortality, unlike
asthma.
The peak Borg score on progressive cycle
ergometry was less correlated with objective
physiological severity as assessed by pulmonary
function or exercise indices, unlike the BDI, in
Table 2. This explains the stronger relationship of
the BDI with mortality, because these physiological
measures have been reported to be factors respon-
sible for predictable mortality.7,10,28 Furthermore,
the relationship between the peak Borg score and
subjective measures of health status and psycholo-
gical disturbances was also weak in the present
study, which contrasted with the results for the
BDI. Dyspnoea is a subjective experience of breath-
ing discomfort caused due to physiological and
psychological interrelationships. In this sense,
dyspnoea during daily activities is a more appro-
priate measurement for evaluating systemic indivi-
dual impairment due to COPD.
These relationships between breathlessness and
clinical measurements were analyzed further by
multiple regression analyses. Although health sta-
tus and lowest oxygen level during exercise
explained 54% of the BDI score, health status and
airflow limitation contributed to only 13% of the
Borg score at the end of exercise. Although the
exercise limitations of COPD are diverse, and
dyspnoea is the main cause, limitations due to
dyspnoea are not universal, and over- or under-
rating in individual patients can be a confounding
issue.29 This is one reason why that type of multiple
regression analysis in the present study was not
significant with regard to peak dyspnoea during
exercise.
When the present study started, peak values
were the primary outcome for dyspnoea ratings
during exercise. However, as we explained, their
predictive and evaluative properties were worse,
and it still remains uncertain what they evaluate.
The current statement30 says that there is more
information available if a range of continuum of
perceptual responses is examined. Therefore, in
addition to peak values, dyspnoea rating at each
minute or work is also necessary in assessing
dyspnoea during exercise.In conclusion, we demonstrated that the rela-
tionships between clinical dyspnoea measures with
activities of daily living and objective and sub-
jective measurements in COPD were stronger than
those of dyspnoea at the end of progressive cycle
ergometry. In addition, this tendency held true for
the relationship between dyspnoea measurements
and mortality. Although both dyspnoea measure-
ments are used as an outcome for exertional
breathlessness in patients with COPD, dyspnoea
during daily activities is considered to evaluate the
disease severity of COPD better than peak dyspnoea
during exercise.References
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